Aliases & Classifications for Ureter, Cancer of

MalaCards integrated aliases for Ureter, Cancer of:

Name: Ureter, Cancer of 56
Ureter Carcinoma 12 54 15 17 71
Malignant Neoplasm of Ureter 71 32
Ureteral Neoplasms 43 71
Ureter Cancer 12 15
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Ureteral Carcinoma 12
Ureteral Neoplasm 17



autosomal dominant


ureter, cancer of:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:11819 DOID:4939
OMIM 56 191600
ICD9CM 34 189.2
MeSH 43 D014516
NCIt 49 C7543 C8993
SNOMED-CT 67 363458004
ICD10 32 C66
MedGen 41 C0153619
SNOMED-CT via HPO 68 126882009 263681008
UMLS 71 C0041955 C0153619 C0600079

Summaries for Ureter, Cancer of

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter, Cancer of, also known as ureter carcinoma, is related to ureter adenocarcinoma and transitional cell carcinoma. An important gene associated with Ureter, Cancer of is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Pathways in cancer and Platinum Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include ureter, kidney and lung, and related phenotypes are neoplasm of the ureter and digestive/alimentary

More information from OMIM: 191600

Related Diseases for Ureter, Cancer of

Diseases related to Ureter, Cancer of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 ureter adenocarcinoma 32.2 KRT7 CEACAM5
2 transitional cell carcinoma 28.9 PLAUR PLAU MSH2 MLH1 KRT7 FGFR3
3 bladder cancer 28.8 TERT PLAUR PLAU NUMA1 MLH1 FGFR3
4 regional ureteric cancer 11.4
5 perforated corneal ulcer 10.5 PLAUR PLAU
6 intratubular embryonal carcinoma 10.4 PLAU KRT7
7 extrahepatic bile duct adenoma 10.4 MSH2 MLH1
8 appendix carcinoid tumor 10.4 MSH2 MLH1
9 familial colorectal cancer 10.4 MSH2 MLH1
10 cervical adenoma malignum 10.4 MSH2 KRT7
11 colorectal cancer, hereditary nonpolyposis, type 6 10.4 MSH2 MLH1
12 jejunal adenocarcinoma 10.3 MLH1 KRT7
13 autosomal dominant non-syndromic intellectual disability 8 10.3 MSH2 MLH1
14 lower lip cancer 10.3 MSH2 MLH1
15 sebaceous gland neoplasm 10.3 MSH2 MLH1
16 sebaceous adenoma 10.3 MSH2 MLH1
17 ileum cancer 10.3 MSH2 KRT7
18 colorectal cancer, hereditary nonpolyposis, type 5 10.3 MSH2 MLH1
19 endometrioid ovary carcinoma 10.3 MSH2 MLH1
20 small intestine adenocarcinoma 10.3 MSH2 MLH1
21 anal fistula 10.3 MSH2 MLH1
22 mixed fibrolamellar hepatocellular carcinoma 10.3 TERT KRT7
23 melanocytic nevus syndrome, congenital 10.3 MSH2 MLH1
24 granulosa cell tumor of the ovary 10.3 TERT KRT7
25 adenomyoma 10.3 MLH1 KRT7
26 dysplastic nevus syndrome 10.2 MSH2 MLH1
27 monophasic synovial sarcoma 10.2 MLH1 KRT7
28 breast-ovarian cancer, familial 1 10.2 MSH2 MLH1
29 urinary tract papillary transitional cell benign neoplasm 10.2 TERT FGFR3
30 bladder papillary transitional cell neoplasm 10.2 TERT FGFR3
31 female reproductive endometrioid cancer 10.2 MSH2 MLH1
32 leukoplakia of penis 10.2 KRT7 CEACAM5
33 urethral villous adenoma 10.2 KRT7 CEACAM5
34 pancreatic foamy gland adenocarcinoma 10.2 KRT7 CEACAM5
35 malignant acrospiroma 10.2 KRT7 CEACAM5
36 mucinous adenofibroma 10.2 KRT7 CEACAM5
37 urinary bladder villous adenoma 10.2 KRT7 CEACAM5
38 cutaneous mucoepidermoid carcinoma 10.2 KRT7 CEACAM5
39 vulva adenocarcinoma 10.2 KRT7 CEACAM5
40 vulval paget's disease 10.2 KRT7 CEACAM5
41 nodular hidradenoma 10.2 KRT7 CEACAM5
42 hidradenoma 10.2 KRT7 CEACAM5
43 cystitis cystica 10.2 KRT7 CEACAM5
44 mucinous intrahepatic cholangiocarcinoma 10.2 KRT7 CEACAM5
45 pancreatic serous cystadenocarcinoma 10.2 KRT7 CEACAM5
46 eccrine adenocarcinoma 10.2 KRT7 CEACAM5
47 renal pelvis adenocarcinoma 10.2 KRT7 CEACAM5
48 external ear carcinoma 10.2 KRT7 CEACAM5
49 anal paget's disease 10.2 KRT7 CEACAM5
50 vaginal tubulovillous adenoma 10.2 KRT7 CEACAM5

Comorbidity relations with Ureter, Cancer of via Phenotypic Disease Network (PDN):

Acute Cystitis Bladder Cancer
Deficiency Anemia Hydronephrosis
Prostatic Hypertrophy Renal Pelvis Carcinoma

Graphical network of the top 20 diseases related to Ureter, Cancer of:

Diseases related to Ureter, Cancer of

Symptoms & Phenotypes for Ureter, Cancer of

Human phenotypes related to Ureter, Cancer of:

# Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 31 HP:0100516

Symptoms via clinical synopsis from OMIM:

G U:
cancer of ureter

Clinical features from OMIM:


MGI Mouse Phenotypes related to Ureter, Cancer of:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 FGFR3 MLH1 MSH2 NR6A1 PLAU TERT
2 neoplasm MP:0002006 9.02 FGFR3 MLH1 MSH2 PLAU TERT

Drugs & Therapeutics for Ureter, Cancer of

Drugs for Ureter, Cancer of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
Gemcitabine Approved Phase 3 95058-81-4 60750
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
Pembrolizumab Approved Phase 3 1374853-91-4
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
Vinblastine Approved Phase 3 865-21-4 241903 13342
ramucirumab Approved, Investigational Phase 3 947687-13-0
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
Cobalamin Experimental Phase 3 13408-78-1 6857388
20 Antineoplastic Agents, Hormonal Phase 3
21 Vitamin B 12 Phase 3
22 Hormone Antagonists Phase 3
23 Hematinics Phase 3
24 Antiemetics Phase 3
25 Vitamin B12 Phase 3
26 glucocorticoids Phase 3
27 BB 1101 Phase 3
28 Gastrointestinal Agents Phase 3
29 Anti-Inflammatory Agents Phase 3
30 Anti-Infective Agents Phase 2, Phase 3
31 Antiviral Agents Phase 2, Phase 3
32 Immunosuppressive Agents Phase 2, Phase 3
33 Antimetabolites Phase 2, Phase 3
34 Albumin-Bound Paclitaxel Phase 3
35 Vitamin B Complex Phase 2, Phase 3
36 Folic Acid Antagonists Phase 2, Phase 3
37 Folate Phase 2, Phase 3
38 Vitamin B9 Phase 2, Phase 3
39 Dermatologic Agents Phase 2, Phase 3
40 Antirheumatic Agents Phase 2, Phase 3
Liposomal doxorubicin Phase 3 31703
42 Mitogens Phase 3
43 Endothelial Growth Factors Phase 3
44 Antineoplastic Agents, Immunological Phase 3
45 Angiogenesis Inhibitors Phase 3
46 Immunoglobulins, Intravenous Phase 3
47 Immunoglobulin G Phase 3
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
2 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
3 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
4 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
5 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
6 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation Recruiting NCT03244384 Phase 3
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
8 An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Active, not recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
9 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
10 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
11 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
12 Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
13 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
14 A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer Completed NCT00661609 Phase 2 AZD4877
15 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder Completed NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
16 A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
17 A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
18 A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Completed NCT00101608 Phase 2 vinflunine
19 A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
20 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
21 Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
22 A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis) Completed NCT00112671 Phase 2 sorafenib tosylate
23 A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00006376 Phase 2 chemotherapy;tipifarnib
24 A Phase II Study of Oxaliplatin in Urothelial Cancer Completed NCT00004203 Phase 2 oxaliplatin
25 A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium Completed NCT00021099 Phase 2 ixabepilone
26 A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER Completed NCT00009867 Phase 2 arsenic trioxide
27 A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract Completed NCT00003175 Phase 2 fluorouracil
29 A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent®) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease Completed NCT00792025 Phase 2 sunitinib malate
30 Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer Completed NCT01031875 Phase 2 pazopanib hydrochloride
31 Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
32 Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997 Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
33 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
34 Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
35 Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
36 Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
37 Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II Completed NCT00014144 Phase 2 gefitinib
38 Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
39 Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00066612 Phase 2 irinotecan hydrochloride
40 A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis) Completed NCT00066352 Phase 2 bortezomib
41 Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
42 A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function. Completed NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
43 A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
44 Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND #61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma Completed NCT00041106 Phase 2 gemcitabine hydrochloride;cisplatin;gefitinib
45 A Phase II Trial Of Adjuvant Chemotherapy For High Risk Transitional Cell Carcinoma Of The Urothelium Completed NCT00028860 Phase 2 carboplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
46 Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00003105 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide;paclitaxel
47 A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
48 A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00310011 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
49 A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy Completed NCT00749892 Phase 2 Erlotinib Hydrochloride
50 A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim

Search NIH Clinical Center for Ureter, Cancer of

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter, Cancer of

Anatomical Context for Ureter, Cancer of

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter, Cancer of:


MalaCards organs/tissues related to Ureter, Cancer of:

Kidney, Lung, Testes, Bone, Liver, Endothelial

Publications for Ureter, Cancer of

Articles related to Ureter, Cancer of:

(show all 32)
# Title Authors PMID Year
Familial occurrence of carcinoma of the ureter. 56
5923294 1966
[Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma]. 54 61
15191676 2004
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]. 61 54
14981816 2004
Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 27 cases. 61
29370814 2018
30662049 2018
[Port-Site Metastasis of an Urothelial Carcinoma after Laparoscopic Nephroureterectomy : A Case Report]. 61
29103252 2017
[Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 24 cases]. 61
28355757 2017
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review. 61
27765044 2016
The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients. 61
27029078 2016
Comprehensive data analysis of human ureter proteome. 61
26937461 2016
[Port-Site Metastasis of Urothelial Carcinoma after Laparoscopic Nephroureterectomy: A Case Report]. 61
27018412 2016
A proteomic glimpse into human ureter proteome. 61
26442468 2016
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. 61
25474136 2014
Pulmonary tumor thrombotic microangiopathy induced by ureteral carcinoma: a necropsy case report. 61
25298767 2014
The impact of real-time 3d imaging by ultra-high speed optical coherence tomography in urothelial carcinoma. 61
24289823 2013
Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. 61
18379418 2008
In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein prefractionation in combination with liquid chromatography-tandem mass spectrometry. 61
17711322 2007
[Ureter cancer of complete double renal pelvis and ureter: a case report]. 61
12613013 2002
Triplicity of the malignant tumor of the urinary bladder. 61
8711348 1994
[Urothelial cancer of the upper urinary tract]. 61
8372411 1993
In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity. 61
8483327 1993
[A study on cathepsin B-like substance in patients with urological cancer]. 61
8464189 1993
[Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ]. 61
1481770 1992
Comparison of radiation sensitivity for three cell lines as measured by the cloning assay and the micro-nucleus test. 61
2260014 1990
Analysis of cell survival after multiple fractions per day and low-dose-rate irradiation of two in vitro cultured rat tumor cell lines. 61
4048393 1985
[Phase II study of cis-diamminedichloroplatinum (II) in genitourinary cancer]. 61
6764107 1982
[An organ-preserving operation in primary ureteral cancer]. 61
7210928 1980
Thermal enhancement of the effectiveness of gamma radiation for induction of reproductive death in cultured mammalian cells. 61
309451 1978
Comparison of three mammalian cell-lines with respect to their sensitivities to hyperthermia, gamma-rays and U.V.-radiation. 61
301514 1977
[Papillary ureter carcinoma as a recurrence of renal pelvis tumor after nephrectomy; diagnosis and therapy]. 61
13399291 1956
[Primary ureter carcinoma]. 61
14380939 1955
[Case report of a metastatic ureter carcinoma]. 61
14397652 1955

Variations for Ureter, Cancer of

Expression for Ureter, Cancer of

Search GEO for disease gene expression data for Ureter, Cancer of.

Pathways for Ureter, Cancer of

Pathways related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.18 TERT MSH2 MLH1 FGFR3
2 10.42 MSH2 MLH1

GO Terms for Ureter, Cancer of

Cellular components related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.46 TERT NUMA1 MSH2 MLH1
2 mismatch repair complex GO:0032300 8.96 MSH2 MLH1
3 specific granule membrane GO:0035579 8.8 STK10 PLAUR PLAU

Biological processes related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 9.4 PLAUR PLAU
2 isotype switching GO:0045190 9.37 MSH2 MLH1
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.32 MSH2 MLH1
4 positive regulation of isotype switching to IgG isotypes GO:0048304 9.26 MSH2 MLH1
5 positive regulation of isotype switching to IgA isotypes GO:0048298 9.16 MSH2 MLH1
6 somatic recombination of immunoglobulin gene segments GO:0016447 8.96 MSH2 MLH1
7 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MSH2 MLH1

Molecular functions related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 9.43 TERT NUMA1 MSH2
2 protein homodimerization activity GO:0042803 9.35 TERT STK10 NR6A1 MSH2 CEACAM5
3 mismatched DNA binding GO:0030983 9.16 MSH2 MLH1
4 guanine/thymine mispair binding GO:0032137 8.62 MSH2 MLH1

Sources for Ureter, Cancer of

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....